PharmArch

In 2022, more than 40% of American adults were recorded as obese. Health experts find this high statistic very concerning as obesity’s harmful effects on the quality of life of many citizens are becoming apparent. Apart from the physical health risks associated with the condition, it also negatively impacts a person’s psyche and mental state. Thus, many turn to medical weight loss treatments for help. Obesity medication has become especially popular in recent years due to its proven efficacy. Studies state that certain obesity medications can influence up to 15% weight loss….

June, 2023,Eccogene (Shanghai) Co. Ltd. (Eccogene) announced that it has received 180 million yuan (approximately $25 million USD) in Series B financing.

When will KarXT be available on the market? Karuna’s drug for schizophrenia,KarXT attracted public attention so much. Investors and patients have great concern on KarXT release date and KarXT FDA approval timeline. According to the most recent news, Karuna plans to submit a New Drug Application (NDA) for KarXT within this year.

Regorafenib was first approved by the FDA in September 2012. It is an oral multi-kinase inhibitor developed by Bayer that targets angiogenic, stromal and oncogenic receptor tyrosine kinase. New application of it is also under research according to the public information [ClinicalTrials.gov Identifier: NCT03793361(Study ID Numbers EREMISS)

Ivonescimab (PD-1/VEGF BsAbs,AK112),  developed independently by Akeso, Inc, is the world’s first PD-1/VEGF bispecific antibody for clinical trail. Ivonescimab injection(AK112) has received 3 breakthrough therapy designation(BTD) for NSCLC.

ALCOA and ALCOA PLUS principles are for Data integrity.
ALCOA: Attributable, Legible, Contemporaneous, Original, Accurate.
ALCOA PLUS: Complete, Consistent, Enduring, Available When Needed.

June, 2023, Guangzhou JOYO Pharma Co., Ltd (JOYO PHARMA)announced that it has completed the pre-C round of financing of more than 100 million yuan.

Cholesgen completed A-round financing of more than 100 million RMB, deeply cultivated the field of cholesterol metabolism. Here is introduction of Cholesgen (Shanghai) Co. Ltd.

On June 5th, Beijing VDJBio Co., Ltd.(VDJBio) announced the completion of its Series C financing round.VDJ-001 is a recombinant humanized monoclonal antibody injection that targets interleukin-6 (IL-6) receptors.

SOP for Responsibilities of the Production Department. All personnel in the Production Department shall implement their respective responsibilities, and the head of the Production Department shall be responsible for supervising the implementation of these responsibilities.